A phase i trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

Haematologica

Volumn 100, Issue 1, 2015, Pages e7-e9

  Assouline, Sarit ^a   Culjkovic Kraljacic, Biljana ^b   Bergeron, Julie ^c   Caplan, Stephen ^a   Cocolakis, Eftihia ^a   Lambert, Caroline ^a   Lau, Cara J ^a   Zahreddine, Hiba Ahmad ^b   Miller, Wilson H ^a   Borden, Katherine L B ^b  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

AML; Drug resistance; eIF4E; Phase I; Ribavirin

Indexed keywords

CYTARABINE; GLUCURONOSYLTRANSFERASE 1A1; INITIATION FACTOR 4E; RIBAVIRIN; TRANSCRIPTION FACTOR GLI1; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LETTER; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; TREATMENT RESPONSE; VERY ELDERLY; CANCER STAGING; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; LEUKEMIA, MYELOID, ACUTE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROGNOSIS; SALVAGE THERAPY; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CYTARABINE; DRUG RESISTANCE, NEOPLASM; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RIBAVIRIN; SALVAGE THERAPY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 84920114537     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.111245     Document Type: Letter

References (11)

1. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74.
2. Carroll M, Borden KL. The oncogene eIF4E: using biochemical insights to target cancer. J Interferon Cytokine Res. 2013;33(5):227-38.
3. Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol. 2008;181(1):51-63.
4. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden K.. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. J Cell Biol. 2005;169(2):245-56.
5. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA. 2004;101(52):18105-10.
6. Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, et al. Further evidence that ribavirin interacts with eIF4E. RNA. 2005; 11(12):1762-6.
7. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009;114(2):257-60.
8. Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 2011; 25(7):1197-200.
9. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 2014; 511(7507):90-3.
10. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65.
11. Kuhlmann J. Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy. Arzneimittel-Forschung. 1982; 32(6):698-704.